Portfolio
Overview

Watchlist
Overview


more

Portfolios Overview New Portfolio
Demo Portfolio
$75,350.00
Total Gain % 149.43%
Total Gain $25,350.00
Total Realised % 0.00%
Total Realised $0.00
Back
Watchlists Overview New Watchlist
Targets
33 Average Rating
Number of Companies 3
Date Created 04 Mar, 2015
Back
Portfolio Summary
Demo Portfolio
Market Value $75,350.00
Total Gain $25,350.00
(149.43%)
Value $42,315.00
Close Price (13 Apr) $141.05
Unrealised P/L (%) 149.40%
Unrealised P/L $25,350.00
Total $75,350.00
$25,350.00
Back
Back
Watchlist Summary
Targets
Short Name TGTS
Date Created 04 Mar, 2015
Current Price $64.95
Added Price $43.06
STRIDE Rating 36
Value Change (%) 50.85%
Current Price $33.88
Added Price $34.64
STRIDE Rating 25
Value Change (%) -2.19%
Current Price $26.74
Added Price $29.27
STRIDE Rating 35
Value Change (%) -8.63%
Total Buy0
Total Hold0
Total Sell3
Back
Back
Filter
Include in Feed
My Portfolios
My Watchlists
STRIDE Lists
Filter Feed By
STRIDE 3D VI
Activity
Upcoming
Warning
Back
Company FilterClear All
Filter by Company Descriptions
Filter by STRIDE Scores
Strength
to
Timing
to
Returns
to
Intrinsic Value
to
Dividends
to
Earnings Predictability
to
Rating
to
Back
Options
Add To Watchlist
Company Info (Sample)
Options
Add To Watchlist

Acceleron Pharma Inc.

Acceleron Pharma Inc.
Pharmaceuticals, Biotechnology and Life Sciences : Biotechnology.
XLRN on Nasdaq Global Market.
Price in US Dollar, all financial data originally reported in US Dollar.
Founded in 2003, the business is 14 years old.
The business last filed accounts on the 01 Mar, 2017.
Company website: www.acceleronpharma.com
Show Company Details
STRIDE Rating
00
Buy
Hold
Sell
United States, Mid Cap
Market Capitalisation: $1,073.87M
Total Enterprise Value: Get a demo
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The company’s therapeutic candidates also include Dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. Read More
Price & Valuation Info
Price Quote on 13th Apr '17
$28.69 2.16(8.14%)
52 Week Range
23.07
41.69
Interactive STRIDE chart with history.
Only available to subscribers.
Get a demo now.
Performance
1 month 0.25 (0.88%)
year-to-date 3.17 (12.42%)
1 year -2.54 (-8.13%)
Show More Valuation Info
Momentum
vs 52week high 69%
vs 50d SMA 107%
vs 200d SMA95%
STRIDE Valuations
Consider Buy Get a demo
Fair Value Get a demo
Consider Sell Get a demo
Price/Adj. Earnings Get a demo
Price/Adj FCF Get a demo
Price/Adj. TBV Get a demo
Forecast Growth Get a demo
Other Valuations
Price/Book Get a demo
Price/Tangible Book Get a demo
Price/Sales Get a demo
Price/Earnings Get a demo
Price/Free Cashflow Get a demo
EV/EBITDA Get a demo
Dividend Yield Get a demo
Volume
Ave. Vol. last 6 months
Hide Extra Info
Scores
S
Strength
T
Timing
R
Returns
I
Intrinsic Value
D
Dividends
E
Earnings Predictability
Other Metrics
Altman Z-Score (Bankruptcy)
Greenblatt Rank (Magic Formula)
Piotroski F-Score (Financial Health)
Beneish M-Score (Earnings Manipulation)
Financials Get a demo
To The Top
Company Options
Add To Watchlist
Watchlists:
Targets
Options
Price Alert Email:
Price to alert at:*
When to alert:*
Cancel
Save
Price Alerts Configured:
Back

Portfolio
Overview

Watchlist
Overview

Feed
Filter


more